Publication year
2013Source
Molecular Immunology, 56, 4, (2013), pp. 675-82ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Rheumatology
Journal title
Molecular Immunology
Volume
vol. 56
Issue
iss. 4
Page start
p. 675
Page end
p. 82
Subject
NCMLS 1: Infection and autoimmunity N4i 4: Auto-immunity, transplantation and immunotherapyAbstract
GM-CSF is a well-known haemopoietic growth factor that is used in the clinic to correct neutropaenia, usually as a result of chemotherapy. GM-CSF also has many pro-inflammatory functions and recent data implicates GM-CSF as a key factor in Th17 driven autoimmune inflammatory conditions. In this review we summarize the findings that have led to the development of GM-CSF antagonists for the treatment of autoimmune diseases like rheumatoid arthritis (RA) and discuss some results of recent clinical trials of these agents.
This item appears in the following Collection(s)
- Academic publications [238586]
- Faculty of Medical Sciences [90409]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.